Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3790645 | 0.85 | — | — | |
| SCHEMBL8379994 | 0.79 | MCL1 (0.39) | TGFBR1 | |
| SCHEMBL1521342 | 0.79 | KDM4E (0.37) | — | |
| SCHEMBL366720 | 0.78 | EGLN1 (0.47) | TGFBR1 | |
| SCHEMBL11139095 | 0.78 | EGLN1 (0.47) | TGFBR1 | |
| SCHEMBL1737637 | 0.77 | TGFBR1 (0.34) | TGFBR1 | |
| SCHEMBL25968074 | 0.77 | TGFBR1 (0.35) | TGFBR1 | |
| SCHEMBL1521749 | 0.77 | KDM4E (0.36) | — | |
| SCHEMBL8376801 | 0.77 | TGFBR1 (0.35) | TGFBR1 | |
| SCHEMBL23641442 | 0.76 | TDP1 (0.37) | TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140212357-A1 | CONJUGATE OF A POLYMER, AN ANTI-ANGIOGENESIS AGENT AND A TARGETING MOIETY, AND USES THEREOF IN THE TREATMENT OF BONE RELATED ANGIOGENESIS CONDITIONS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2014-07-31 | — | — | US | disclosed |
| US-8703114-B2 | Conjugate of a polymer, an anti-angiogenesis agent and a targeting moiety, and uses thereof in the treatment of bone related angiogenesis conditions | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2014-04-22 | — | — | US | disclosed |
| US-20110085979-A1 | CONJUGATE OF A POLYMER, AN ANTI-ANGIOGENESIS AGENT AND A TARGETING MOIETY, AND USES THEREOF IN THE TREATMENT OF BONE RELATED ANGIOGENESIS CONDITIONS | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-04-14 | — | — | US | disclosed |
| EP-2210616-A1 | Multifunctional stealth nanoparticles for biomedical use | Centre National de la Recherche Scientifique (FR) | 2010-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140212357-A1 | CONJUGATE OF A POLYMER, AN ANTI-ANGIOGENESIS AGENT AND A TARGETING MOIETY, AND USES THEREOF IN THE TREATMENT OF BONE RELATED ANGIOGENESIS CONDITIONS | VEGFA, MVD, FLT1 | TGFBR1 2496/4885 |
| US-20110085979-A1 | CONJUGATE OF A POLYMER, AN ANTI-ANGIOGENESIS AGENT AND A TARGETING MOIETY, AND USES THEREOF IN THE TREATMENT OF BONE RELATED ANGIOGENESIS CONDITIONS | VEGFA, MVD, FLT1 | TGFBR1 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.